open access

Vol 1, No 1 (2004)
Review paper
Published online: 2004-04-26
Get Citation

Atypical antipsychotics in the management of bipolar disorder

Barbara Sęp-Kowalikowa, Monika Czucha
Psychiatria 2004;1(1):1-7.

open access

Vol 1, No 1 (2004)
Prace poglądowe - nadesłane
Published online: 2004-04-26

Abstract

This article is based on available papers about the use of atypical antipsychotics in bipolar disorders and the authors’ first experiences in this field. Atypical antipsychotics were used in 12 patients. Eight of them were young and treated with psychiatric drugs for the first time for manic episode. They had a history of 2–3 untreated depressive episodes. The observation lasted 1–2.5 years. In all cases we observed very rapid improvement, in acute phase then in one case the monotherapy with atypical antipsychotic was continued, the rest of patients received the combination therapy with SSRI and mood-stabilizing drug. In 3 of 4 other patients with the long-term history of mixed states and psychotic symptoms the therapy with atypical antipsychotic allowed to stabilize the mental state. In one case, a 50-year woman, we observed resistance to the treatment and administration of atypical antipsychotic was associated with no treatment effect and caused exacerbation of the symptoms.

Abstract

This article is based on available papers about the use of atypical antipsychotics in bipolar disorders and the authors’ first experiences in this field. Atypical antipsychotics were used in 12 patients. Eight of them were young and treated with psychiatric drugs for the first time for manic episode. They had a history of 2–3 untreated depressive episodes. The observation lasted 1–2.5 years. In all cases we observed very rapid improvement, in acute phase then in one case the monotherapy with atypical antipsychotic was continued, the rest of patients received the combination therapy with SSRI and mood-stabilizing drug. In 3 of 4 other patients with the long-term history of mixed states and psychotic symptoms the therapy with atypical antipsychotic allowed to stabilize the mental state. In one case, a 50-year woman, we observed resistance to the treatment and administration of atypical antipsychotic was associated with no treatment effect and caused exacerbation of the symptoms.
Get Citation

Keywords

atypical antypsychotic; bipolar disorders

About this article
Title

Atypical antipsychotics in the management of bipolar disorder

Journal

Psychiatria (Psychiatry)

Issue

Vol 1, No 1 (2004)

Article type

Review paper

Pages

1-7

Published online

2004-04-26

Bibliographic record

Psychiatria 2004;1(1):1-7.

Keywords

atypical antypsychotic
bipolar disorders

Authors

Barbara Sęp-Kowalikowa
Monika Czucha

References (25)
  1. Greenblatt HK, Greenblatt DJ. Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. Clin Pharmacol Drug Dev. 2018; 7(3): 228–232.
  2. Moon DE, Lee DIk, Lee SC, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010; 32(14): 2370–2385.
  3. Mayor S. Pregabalin and gabapentin become controlled drugs to cut deaths from misuse. BMJ. 2018; 363: k4364.
  4. Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017; 77(4): 403–426.
  5. Schjerning O, Pottegård A, Damkier P, et al. Use of pregabalin - a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry. 2016; 49(4): 155–161.
  6. Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017; 32(1): 49–55.
  7. Montgomery SA, Lyndon G, Almas M, et al. Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis. Int Clin Psychopharmacol. 2017; 32(1): 41–48.
  8. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2015.
  9. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007; 29(1): 26–48.
  10. Ströhle A, Gensichen J, Domschke K. The diagnosis and treatment of anxiety disorders. Dtsch Arztebl Int. 2018; 155(37): 611–620.
  11. Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018; 19(10): 1057–1070.
  12. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017; 19(2): 93–107.
  13. Perna G, Alciati A, Riva A, et al. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep. 2016; 18(3): 23.
  14. Meier SM, Petersen L, Mattheisen M, et al. Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark. Lancet Psychiatry. 2015; 2(6): 515–523.
  15. Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol. 2015; 29(10): 1047–1060.
  16. Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018; 3: CD011481.
  17. Ruiz MA, Álvarez E, Carrasco JL, et al. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Des Devel Ther. 2015; 9: 4329–4340.
  18. Ruiz M, Álvarez E, Carrasco J, et al. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Design, Development and Therapy. 2015: 4329.
  19. Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs. 2012; 21(9): 1243–1245.
  20. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014; 5(1): 38–56.
  21. Erdoğan C, Ongun N, Tümkaya S, et al. What is the real effect of pregabalin in patients with diabetic neuropathic pain?(Do patients suffer from less pain or do they less care about it?). Ideggyogy Sz. 2018; 71(5-06): 213–216.
  22. Ogawa S, Arakawa A, Hayakawa K, et al. Pregabalin for Neuropathic Pain: Why Benefits Could Be Expected for Multiple Pain Conditions. Clin Drug Investig. 2016; 36(11): 877–888.
  23. Kozubski W, Liberski P, Moryś J, Neurologia T. Neurologia. T. 1-2. PZWL, Warszawa 2013.
  24. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand. 2004; 110(4): 207–220.
  25. Swisher CB, Doreswamy M, Husain AM. Use of pregabalin for nonconvulsive seizures and nonconvulsive status epilepticus. Seizure. 2013; 22(2): 116–118.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl